Merck, Moderna claim ‘promising’ skin cancer vaccine results in key trial
Both the FDA and the European Medicines Agency have placed the therapy on an expedited review pathway.
We haven't written up this one. Toronto Sun has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.